β Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
βΉοΈ Info
π§Ύ At a Glance π Core Facts ποΈ Products/Services β Ratings π§βπΌ Executives π¬ My Commentsπ‘ Analytics
π Insights π’ Company Q&A (464) π οΈ Industry Q&A (98) π Competitors π Price Low π Price Swings β‘ SWOT ποΈ PEST π Porter's Five Forces β¨ Score Positive β οΈ Risk Assessment π§© Segmentation π Ά Google Linksπ Ratios
π° Margins π Financial Ratios π± Growth π Enterprise Value π Key Metrics π΅ Dividendsπ§ Tools
β Due Diligenceπ§© Revenue Segmentation by Product
Switch to Location
Fiscal year | Segment | Value |
---|---|---|
2024 | Veklury | 1.8B |
2024 | Products, Other HIV | 19.61B |
2024 | Other Products, Total Other product sales | 889M |
2024 | Trodelvy | 1.32B |
2024 | Cell Therapy Products, Total Cell Therapy Product Sales | 2.38B |
2023 | Hepatitis B Virus / Hepatitis Delta Virus Product | 1.02B |
2023 | Veklury | 2.18B |
2023 | Products, Other HIV | 18.23B |
2023 | Other Products, Total Other product sales | 859M |

π° Explore more revenue segmentation data for Gilead Sciences!
Sign up for free or log inπ₯ Free eBook for new users: "The Checklist Value Investor β A Smarter Way to Pick Stocks"